CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Coherus Oncology reports 89% confirmed response rate for tagmokitug combination in first-line esophageal cancer trial

By Public Technologies
  • Coherus Oncology announced interim tagmokitug trial results on October 28, 2026, supporting expanded enrollment in first- and second-line esophageal cancer cohorts.
  • First-line treatment with toripalimab and chemotherapy showed tumor responses regardless of PD-L1 status; second-line treatment showed durable clinical benefit.
  • Safety findings showed manageable tolerability with no new safety signals, supporting continued development.
  • Further evaluation will assess response durability, progression-free survival and biomarkers as the data mature.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coherus Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-119912), on October 29, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk